Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Mar 28:13:164.
doi: 10.1186/1471-2407-13-164.

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

Lucia Del Mastro  1 , Alessandra Fabi, Mauro Mansutti, Michele De Laurentiis, Antonio Durando, Domenico Franco Merlo, Paolo Bruzzi, Ignazia La Torre, Matteo Ceccarelli, Gbenga Kazeem, Paolo Marchi, Davide Boy, Marco Venturini, Sabino De Placido, Francesco Cognetti
Affiliations
Clinical Trial

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

Lucia Del Mastro et al. BMC Cancer. .

Abstract

Background: This open-label study compared docetaxel/gemcitabine vs. paclitaxel/gemcitabine and a weekly (W) vs. 3-weekly (3 W) schedule in metastatic breast cancer (MBC).

Methods: Patients relapsed after adjuvant/neoadjuvant anthracycline-containing chemotherapy were randomized to: A) gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W; B) gemcitabine 1250 mg/m2 Day 1,8 + paclitaxel 175 mg/m2 Day 1 q3W; C) gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W; D) gemcitabine 800 mg/m2 Day 1,15 + paclitaxel 80 mg/m2 Day 1,8,15 q4W. Primary endpoint was time-to-progression (TTP). Secondary endpoints were overall survival (OS) and overall response rate (ORR).

Results: Interim analysis led to accrual interruption (241 patients enrolled of 360 planned). Median TTP (months) was 8.33 (95% CI: 6.19-10.16) with W and 7.51 (95% CI: 5.93-8.33) with 3 W (p=0.319). No differences were observed in median TTP between docetaxel and paclitaxel, with 85.6% and 87.0% of patients progressing, respectively. OS did not differ between regimens/schedules. ORR was comparable between regimens (HR: 0.882; 95% CI: 0.523-1.488; p=0.639), while it was significantly higher in W than in the 3 W (HR: 0.504; 95% CI: 0.299-0.850; p=0.010) schedule. Grade 3/4 toxicities occurred in 69.2% and 71.9% of patients on docetaxel and paclitaxel, and in 65.8% and 75.2% in W and 3 W.

Conclusions: Both treatment regimens showed similar TTP. W might be associated with a better tumour response compared with 3 W.

Trial registration: Clinicaltrial.gov ID NCT00236899.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients disposition and reasons for study discontinuation.
Figure 2
Figure 2
Results of time-to-progression (TTP) by treatment schedule (Weekly vs. 3-Weekly). Number of patients still at risk for 3-weekly (1) and weekly (2) treatment schedule are reported above the X axis.
Figure 3
Figure 3
Results of time-to-progression by treatment regimen (gemcitabine+docetaxel vs. gemcitabine+paclitaxel). Number of patients still at risk for 3-weekly (1) and weekly (2) treatment regimen are reported above the X axis.
Figure 4
Figure 4
Results of time-to-progression by treatment arm (gemcitabine+docetaxel vs. gemcitabine+paclitaxel). Number of patients still at risk for each treatment arm (1 - Arm A: docetaxel and gemcitabine 3 weekly; 2 - Arm C: docetaxel and gemcitabine weekly 3 - Arm B: paclitaxel and gemcitabine 3 weekly; 4 - Arm D: paclitaxel and gemcitabine weekly) are reported above the X axis.
See this image and copyright information in PMC

References

    1. Cardoso F, Fallowfield L, Costa A. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi25–30. - PubMed
    1. Albain KS, Nag SM, Calderillo-Ruiz G. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–3957. doi: 10.1200/JCO.2007.11.9362. - DOI - PubMed
    1. O’Shaughnessy J, Miles D, Vukelja S. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812–2823. doi: 10.1200/JCO.2002.09.002. - DOI - PubMed
    1. Chan S, Romieu G, Huober J. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009;27(11):1753–1760. doi: 10.1200/JCO.2007.15.8485. - DOI - PubMed
    1. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990;62(6):1034–1038. doi: 10.1038/bjc.1990.434. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data